A Phase 3 study evaluating the efficacy of CSL112, an intravenous formulation of human apoA-I derived from plasma, to reduce cardiovascular risks for individuals with recent myocardial infarction. 

• Successfully enrolled 18,226 patients in 46 countries worldwide with only 2 patients lost to follow up
• DCRI managed 193 US sites that enrolled more than 1,800 high-risk acute MI patients, much of it during COVID-19 pandemic, with no patients lost to follow-up in the US.
• A collaborative effort from the DCRI Faculty, Project Management, Site Management / Monitoring, Data Management, Research Together Patient Advisory Group, and Statistical Risk Based Monitoring with sponsor and partners including:
  • Baim Institute for Clinical Research
  • Canadian Vigour Centre (CVC)
  • CSL Behring
  • Green Lane Coordinating Center (GLCC – New Zealand)
  • South Australian Health and Medical Research Institute (SAHMRI - Australia)
  • Fortrea